Imclone Systems IMCL
-
Dendreon Goes On The Offensive
… Pharmaceuticals ( SVNT ) and president of Eli Lilly & Company's ( LLY ) Oncology Unit following the company's 2008 acquisition of Imclone Systems . Prior to joining Imclone, he served as the Company Group Chairman of Biopharmaceuticals within Johnson & Johnson ( JNJ …
-
Krill Oil Based Drug Candidate Could Unseat Glaxo's Blockbuster Lovaza
… in industrialized societies than in developing nations. Dr. Harlan W. Waksal, who helped launch and later re-build ImClone Systems Incorporated into a successful biotech powerhouse (and now a wholly-owned subsidiary of Eli Lilly and Company) sees …
-
Calling for Common Sense on Cell Phone Taxes
… Administration approved cancer drug Erbitux on Thursday, fulfilling a long-awaited goal for Bristol-Myers Squibb BMY and Imclone IMCL . Our fair value estimate for Bristol already assumed Erbitux's approval. The FDA approved Erbitux as a second line of defense …
-
Exenatide Once-Weekly On Track
… news, Lilly announced that it would take a $4 billion-plus charge in the fourth quarter related to its acquisition of Imclone Systems , representing more than 60% of the purchase price. We had already accounted for the value destroyed by Lilly's acquisition …
-
First Impression of Bristol's 3Q
… proceeds from the ConvaTec sale. Bristol expects to receive another $1 billion from Eli Lilly's LLY acquisition of its Imclone IMCL shares. Having been outbid for Imclone, Bristol may look to deploy this cash in another acquisition at a better price.
-
Lilly to Buy Imclone
We were surprised by Eli Lilly's LLY announcement Monday that the firm has agreed to acquire Imclone IMCL for $70 per share. Imclone's board has accepted Lilly's offer, which is well above Bristol-Myers Squibb's BMY outstanding …
-
Bristol Makes Second Bid for Imclone
Bristol-Myers Squibb BMY has announced that it plans to initiate a $62 per share tender offer for Imclone Systems IMCL , appealing directly to shareholders in an effort to bypass the concerns of Imclone board chairman Carl Icahn …
-
Mystery Bidder Tops Bristol's Imclone Bud
Imclone's IMCL board, led by chairman Carl Icahn, has determined that Bristol-Myers Squibb's BMY $60-per-share offer for the firm is …
-
Bristol Makes Offer for Imclone
Bristol-Myers Squibb BMY made a $4.5 billion all-cash offer Thursday to acquire the 83% of Imclone IMCL shares it doesn't already own. The $60 per share offer represents a 30% premium to yesterday's closing price, and Imclone …
-
Nektar Putting Exubera in the Past
… with a mutation in the KRAS gene--that is, patients who aren't likely to respond to popular therapies such as Imclone's IMCL Erbitux. Nektar's pulmonary technology could also see a revival in the wake of Exubera; Nektar and partner Bayer BAYRY are …